166 related articles for article (PubMed ID: 29033940)
1. PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8
Bowers JS; Majchrzak K; Nelson MH; Aksoy BA; Wyatt MM; Smith AS; Bailey SR; Neal LR; Hammerbacher JE; Paulos CM
Front Immunol; 2017; 8():1221. PubMed ID: 29033940
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8
Dwyer CJ; Arhontoulis DC; Rangel Rivera GO; Knochelmann HM; Smith AS; Wyatt MM; Rubinstein MP; Atkinson C; Thaxton JE; Neskey DM; Paulos CM
Eur J Immunol; 2020 Sep; 50(9):1386-1399. PubMed ID: 32383488
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.
Nelson MH; Bowers JS; Bailey SR; Diven MA; Fugle CW; Kaiser AD; Wrzesinski C; Liu B; Restifo NP; Paulos CM
J Immunother Cancer; 2016; 4():6. PubMed ID: 26885368
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
5. β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.
Majchrzak K; Nelson MH; Bowers JS; Bailey SR; Wyatt MM; Wrangle JM; Rubinstein MP; Varela JC; Li Z; Himes RA; Chan SS; Paulos CM
JCI Insight; 2017 Apr; 2(8):. PubMed ID: 28422756
[TBL] [Abstract][Full Text] [Related]
6. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model.
He H; Wisner P; Yang G; Hu HM; Haley D; Miller W; O'Hara A; Alvord WG; Clegg CH; Fox BA; Urba WJ; Walker EB
J Transl Med; 2006 Jun; 4():24. PubMed ID: 16772043
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections.
Gracias DT; Boesteanu AC; Fraietta JA; Hope JL; Carey AJ; Mueller YM; Kawalekar OU; Fike AJ; June CH; Katsikis PD
J Immunol; 2016 Feb; 196(3):1186-98. PubMed ID: 26740110
[TBL] [Abstract][Full Text] [Related]
8.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment with cyclophosphamide or OX40 (CD134) costimulation targeting regulatory T cell function enhances the anti-tumor immune effect of adoptively transferred CD8+ T cells from wild-type mice.
Ueki T; Murata S; Kitamura N; Mekata E; Tani T
Mol Med Rep; 2009; 2(4):615-20. PubMed ID: 21475875
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro.
Pham Minh N; Murata S; Kitamura N; Ueki T; Kojima M; Miyake T; Takebayashi K; Kodama H; Mekata E; Tani M
Int J Cancer; 2018 Jun; 142(11):2335-2343. PubMed ID: 29313971
[TBL] [Abstract][Full Text] [Related]
11. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
12. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
13. Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.
Blake SJ; Ching AL; Kenna TJ; Galea R; Large J; Yagita H; Steptoe RJ
PLoS One; 2015; 10(3):e0119483. PubMed ID: 25741704
[TBL] [Abstract][Full Text] [Related]
14. PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation.
Haylock-Jacobs S; Comerford I; Bunting M; Kara E; Townley S; Klingler-Hoffmann M; Vanhaesebroeck B; Puri KD; McColl SR
J Autoimmun; 2011 May; 36(3-4):278-87. PubMed ID: 21396797
[TBL] [Abstract][Full Text] [Related]
15. Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8
Sanz-Ortega L; Portilla Y; Pérez-Yagüe S; Barber DF
J Nanobiotechnology; 2019 Aug; 17(1):87. PubMed ID: 31387604
[TBL] [Abstract][Full Text] [Related]
16. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
17. The p110 delta isoform of phosphatidylinositol 3-kinase controls the quality of secondary anti-Leishmania immunity by regulating expansion and effector function of memory T cell subsets.
Liu D; Uzonna JE
J Immunol; 2010 Mar; 184(6):3098-105. PubMed ID: 20154209
[TBL] [Abstract][Full Text] [Related]
18. Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8⁺ T cells.
Hosoi H; Ikeda H; Imai N; Amaike C; Wang L; Orito Y; Yamane M; Ueno H; Ideno M; Nukaya I; Enoki T; Mineno J; Takesako K; Hirano S; Shiku H
Eur J Immunol; 2014 Jun; 44(6):1747-58. PubMed ID: 24723437
[TBL] [Abstract][Full Text] [Related]
19. Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells.
Tanaka T; Watanabe S; Takahashi M; Sato K; Saida Y; Baba J; Arita M; Sato M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Kondo R; Aoki N; Ohshima Y; Sakagami T; Abe T; Moro H; Koya T; Tanaka J; Kagamu H; Yoshizawa H; Kikuchi T
PLoS One; 2017; 12(8):e0183976. PubMed ID: 28854279
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies.
Liu X; Wang A; Liang X; Liu J; Zou F; Chen C; Zhao Z; Deng Y; Wu H; Qi Z; Wang B; Wang L; Liu F; Xu Y; Wang W; Fernandes SM; Stone RM; Galinsky IA; Brown JR; Loh T; Griffin JD; Zhang S; Weisberg EL; Zhang X; Liu J; Liu Q
Oncotarget; 2016 Aug; 7(33):53515-53525. PubMed ID: 27447747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
